Sellas Life Sciences Shares Rise 7.6% on Fast Track Designation for Cancer Treatment by FDA
By Denny Jacob
Sellas Life Sciences shares ticked up 7.6% to $1 following a fast track designation granted to SLS009 by the Food and Drug Administration.
The stock is down 57% this year, and hit a 52-week low last week
The late-stage clinical biopharmaceutical company's SLS009 is a CDK9 inhibitor for the treatment of relapsed/refractory peripheral T-cell lymphomas, a group of aggressive and rare non-Hodgkin lymphomas.
Sellas said it's also pursuing potential breakthrough therapy designation from the FDA for SLS009 to treat relapsed/refractory peripheral T-cell lymphomas. It has a scheduled meeting with the regulator in the fourth quarter.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 30, 2023 12:07 ET (16:07 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom